Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 4 EP applications Mads Damsgaard has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13815781

AMINOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS

IPC classification:
A61K 31/4439, A61K 31/444, A61K 31/497, A61P 25/16, A61P 35/00, C07D 401/04, C07D 401/14, C07D 403/14, C07D 413/04, C07D 413/14
Applicant:
H. Lundbeck A/S
Agent:
Mads Damsgaard, H. Lundbeck A/S
Status:
The patent has been granted
EP14702497

N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS

IPC classification:
A61K 31/44, A61K 31/4402, A61K 31/4406, A61P 25/00, C07D 213/60, C07D 213/65, C07D 401/04, C07D 403/04, C07D 417/04
Applicant:
H. Lundbeck A/S
Agent:
Mads Damsgaard, H. Lundbeck A/S
Status:
GRANT OF PATENT INTENDED
EP14720062

ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS

IPC classification:
A61K 31/437, A61P 25/00, A61P 35/00, A61P 37/00, C07D 471/04
Applicant:
H. Lundbeck A/S
Agent:
Mads Damsgaard, H. Lundbeck A/S
Status:
The patent has been granted
EP11725865

MODULATION OF THE INTERACTION BETWEEN SORLA AND GDNF-FAMILY LIGAND RECEPTORS

IPC classification:
A61K 38/00, A61K 38/18, C07K 16/28
Applicant:
H. Lundbeck A/S
Agent:
Mads Damsgaard, H. Lundbeck A/S
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT

Please Sign in to use this feature